Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR. The company reached nearly 0.5 ...

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

Q4 2024 Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in ...

2025 EPS Guidance: $8.88 to $9.03. Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR.